Seattle, WA – According to filings with the U.S. Securities and Exchange Commission, TwinStrand Biosciences is raising $16,301,834.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jesse Salk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TwinStrand Biosciences

At TwinStrand Biosciences we are using Duplex Sequencing Technology to detect ultra-rare variants that are invisible by other sequencing approaches. We are applying our technology to a new generation of high-accuracy clinical diagnostics and innovative tools for scientific discovery.

To learn more about TwinStrand Biosciences, visit http://www.twinstrandbio.com/

Contact:
Jesse Salk, Chief Executive Officer
617-959-1959
jsalk@twinstrandbio.com
https://www.linkedin.com/in/jesse-salk/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved